These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23933691)

  • 21. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
    Ge R; Xu X; Xu P; Li L; Li Z; Bian J
    Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular biology of castration-resistant prostate cancer].
    Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
    Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.
    Ponnusamy S; Coss CC; Thiyagarajan T; Watts K; Hwang DJ; He Y; Selth LA; McEwan IJ; Duke CB; Pagadala J; Singh G; Wake RW; Ledbetter C; Tilley WD; Moldoveanu T; Dalton JT; Miller DD; Narayanan R
    Cancer Res; 2017 Nov; 77(22):6282-6298. PubMed ID: 28978635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen action and metabolism in prostate cancer.
    Green SM; Mostaghel EA; Nelson PS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
    Anantharaman A; Friedlander TW
    Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
    Blas L; Shiota M
    Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
    Fiandalo MV; Wu W; Mohler JL
    Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the androgen receptor and overcoming resistance in prostate cancer.
    Einstein DJ; Arai S; Balk SP
    Curr Opin Oncol; 2019 May; 31(3):175-182. PubMed ID: 30893145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
    Lamb AD; Massie CE; Neal DE
    BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular genetic mechanisms of drug resistance in prostate cancer].
    Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
    Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
    Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
    Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer.
    Martinez-Ariza G; Hulme C
    Pharm Pat Anal; 2015; 4(5):387-402. PubMed ID: 26389532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
    Hofer MD
    Fundam Clin Pharmacol; 2018 Oct; 32(5):547. PubMed ID: 30209857
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.
    Schweizer MT; Plymate SR
    Expert Opin Ther Targets; 2016 Aug; 20(8):903-6. PubMed ID: 26927611
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer: AR-V7 status in CTCs is a treatment-specific biomarker.
    Stone L
    Nat Rev Urol; 2016 Aug; 13(8):433. PubMed ID: 27349368
    [No Abstract]   [Full Text] [Related]  

  • 40. [Sequential therapy for castration-resistant prostate cancer].
    Nozawa M; Uemura H
    Nihon Rinsho; 2016 May; 74 Suppl 3():644-8. PubMed ID: 27344809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.